Last reviewed · How we verify

morphine and droperidol

Dr.med. Sabine Schoenfeld · FDA-approved active Small molecule

morphine and droperidol is a Opioid analgesic with antipsychotic/antiemetic Small molecule drug developed by Dr.med. Sabine Schoenfeld. It is currently FDA-approved for Moderate to severe acute pain, Perioperative analgesia and anxiolysis. Also known as: DHBP.

Morphine provides opioid analgesia by binding mu opioid receptors, while droperidol is a butyrophenone antipsychotic that blocks dopamine receptors to reduce nausea and anxiety.

Morphine provides opioid analgesia by binding mu opioid receptors, while droperidol is a butyrophenone antipsychotic that blocks dopamine receptors to reduce nausea and anxiety. Used for Moderate to severe acute pain, Perioperative analgesia and anxiolysis.

At a glance

Generic namemorphine and droperidol
Also known asDHBP
SponsorDr.med. Sabine Schoenfeld
Drug classOpioid analgesic with antipsychotic/antiemetic
TargetMu opioid receptor (morphine); dopamine D2 receptor (droperidol)
ModalitySmall molecule
Therapeutic areaPain Management, Anesthesia
PhaseFDA-approved

Mechanism of action

This combination product pairs morphine, a mu opioid receptor agonist that modulates pain perception in the central nervous system, with droperidol, a dopamine antagonist that provides antiemetic and anxiolytic effects. Droperidol's dopamine blockade at the chemoreceptor trigger zone reduces opioid-induced nausea and vomiting, while also providing sedation and anxiolysis to complement morphine's analgesic action.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about morphine and droperidol

What is morphine and droperidol?

morphine and droperidol is a Opioid analgesic with antipsychotic/antiemetic drug developed by Dr.med. Sabine Schoenfeld, indicated for Moderate to severe acute pain, Perioperative analgesia and anxiolysis.

How does morphine and droperidol work?

Morphine provides opioid analgesia by binding mu opioid receptors, while droperidol is a butyrophenone antipsychotic that blocks dopamine receptors to reduce nausea and anxiety.

What is morphine and droperidol used for?

morphine and droperidol is indicated for Moderate to severe acute pain, Perioperative analgesia and anxiolysis.

Who makes morphine and droperidol?

morphine and droperidol is developed and marketed by Dr.med. Sabine Schoenfeld (see full Dr.med. Sabine Schoenfeld pipeline at /company/dr-med-sabine-schoenfeld).

Is morphine and droperidol also known as anything else?

morphine and droperidol is also known as DHBP.

What drug class is morphine and droperidol in?

morphine and droperidol belongs to the Opioid analgesic with antipsychotic/antiemetic class. See all Opioid analgesic with antipsychotic/antiemetic drugs at /class/opioid-analgesic-with-antipsychotic-antiemetic.

What development phase is morphine and droperidol in?

morphine and droperidol is FDA-approved (marketed).

What are the side effects of morphine and droperidol?

Common side effects of morphine and droperidol include Respiratory depression, Hypotension, Sedation, Nausea and vomiting, Dizziness, QT prolongation (droperidol).

What does morphine and droperidol target?

morphine and droperidol targets Mu opioid receptor (morphine); dopamine D2 receptor (droperidol) and is a Opioid analgesic with antipsychotic/antiemetic.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing